340B Drug Pricing Program
The AHA today urged the Supreme Court of the United States to reverse the 2020 federal appeals court decision that upheld the authority of the Department of Health and Human Services to significantly cut payments to certain hospitals that participate in the 340B Drug Pricing Program.
The AHA urged The Supreme Court of the United States to reverse the 2020 federal appeals court decision that upheld the authority of the Department of Health and Human Services to significantly cut payments to certain hospitals that participate in the 340B Drug Pricing Program.
The Centers for Medicare & Medicaid Services July 19 released its calendar year 2022 outpatient prospective payment system/ambulatory surgical center proposed rule.
CMS Issues Hospital Outpatient/ASC Proposed Rule, Including Modifications to Price Transparency Rule
Download the AHA Special Bulletin:
CMS Issues Hospital Outpatient/ASC Proposed Rule,
Including Modifications to Price Transparency Rule
Congress is currently considering legislation that would provide temporary relief for any hospitals participating in the 340B program that had to leave the program due to patient mix changes as a result of the COVID-19 pandemic.
Congress is currently considering legislation that would provide temporary relief for any hospitals participating in the 340B program that had to leave the program due to changes in their patient mix as a result of the COVID-19 pandemic.
The Supreme Court of the United States today decided to take up AHA’s petition asking to reverse a federal appeals court decision that significantly cuts payments to certain hospitals that participate in the 340B Drug Pricing Program, threatening access to care in communities.
We are pleased that the U.S. Supreme Court has agreed to hear the compelling arguments in our case on payments cuts to the 340B drug pricing program that are adversely impacting care to patients.
Amicus Brief Eli Lilly v Cochran Re 340B Contract Pharmacy – Intervention filed June 23, 2021.
Amicus Brief NOVO NORDISK v Cochran Re 340B Contract Pharmacy – Intervention